The plant has been designed to meet the world’s most stringent regulatory standards.
The goal of the design specifications for CiplaQCIL is to produce pharmaceutical products of the highest quality that have zero environmental impact, adhere to current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP), all consistent with global, regional and local regulatory standards.
To sustainably a leader in the provision of sustainable, quality and affordable regional solutions to regional health concerns.
To become a Centre of excellence in manufacturing quality and affordable medicines for Sub–Saharan Africa
Cipla Quality Chemical Industries Limited (CiplaQCIL) is a state of the art pharmaceutical plant that manufactures the latest Anti-retroviral (ARVs), Anti-malarial (ACTs) and Hepatitis B medicines. CiplaQCIL was established in 2005 as a joint venture company between Cipla Ltd of India and Quality Chemicals Ltd (QCL) of Uganda
The venture attracted two other international investors namely; Capitalworks Investment and TLG Capital Investments of Mauritius. In 2013, QCL entered into a strategic partnership with Cipla where the Indian company acquired more shares in an effort to enhance technology and knowledge transfer.
The establishment of the pharmaceutical plant is in line with the Pharmaceutical manufacturing Plan of Action for Africa, the East African Pharmaceutical Manufacturing Plan of Action and the Millenium Development Goals. The plant seeks to take advantage of the flexibilities provided by the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), for access to affordable, newer and safer medicines for the poor.
CiplaQCIL’s World Health Organization (WHO) approved facility stands as a testament to the possibilities of pharmaceutical manufacturing in Africa.